STERIS

STERIS Plc engages in the provision of healthcare and life science product and service solutions. It operates through the following segments: Healthcare, Life Sciences, Applied Sterilization Technologies, and Dental. The Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. The Life Sciences segment designs, manufactures, and sells consumable products, equipment maintenance, specialty services, and capital equipment. The Applied Sterilization Technologies segment is involved in contract sterilization and testing services for medical device and pharmaceutical manufacturers. The Dental segment provides a comprehensive offering for dental practitioners and dental schools, offering instruments, infection prevention consumables and instrument management systems. The company was founded in 1985 and is headquartered in Mentor, OH.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

STERIS plc reports 16% revenue growth and anticipates 7-8% growth in fiscal 2024

STERIS plc's Q4 2023 earnings call highlighted strong revenue growth, successful integration of Cantel Medical, and cost synergies exceeding projections. While challenges exist in the AST segment and concerns were raised about labor costs and free cash flow pressure, the outlook for fiscal 2024 indicates potential opportunities for growth.

STERIS plc reports mixed Q2 performance, optimistic about future opportunities

STERIS plc's Q2 2023 earnings call highlighted mixed performance across segments, with strong growth in Healthcare but challenges in the AST and Dental segments. The company remains optimistic about future opportunities, particularly with the Becton, Dickinson deal and updated financial outlook.

STERIS reports Q3 growth, faces margin pressures and supply challenges

STERIS delivered solid revenue growth despite challenges from divestitures and margin pressures.
The company's strategic acquisitions and focus on direct market access position it for future growth.
While facing some headwinds, STERIS remains confident in its long-term growth prospects.
Investors should monitor how the company navigates supply chain strains and capitalizes on bioprocessing demand.

STERIS reports strong Q4 earnings, eyes growth amid challenges

STERIS delivered robust Q4 2023 results with strong revenue growth and net income.
While facing challenges in certain segments, the company remains optimistic about growth opportunities.
Confidence in compliance with EPA regulations and a positive outlook for fiscal 2024.
Strategic capital allocation decisions and cost synergies driving financial performance.

STERIS reports solid Q1 earnings, eyes growth through acquisitions

STERIS' Q1 2024 performance was solid, driven by revenue growth in the healthcare segment. Challenges were seen in the AST and Dental segments due to inventory destocking. The upcoming acquisition and positive growth expectations in Life Sciences present opportunities for future growth.

STERIS reports strong Q2 performance amidst segment challenges

STERIS showcased robust financial performance in Q2 2024, driven by strong organic revenue growth and solid net income. While facing challenges in certain segments, the company remains optimistic about future growth opportunities and is actively managing its debt and cash flow.

STERIS reports strong Q3 earnings, updates 2024 outlook positively

STERIS showcased solid performance in Q3 2024, driven by strong healthcare and life sciences segments. Challenges in AST and Dental segments were noted, with opportunities seen in updated fiscal 2024 outlook and strategic discussions on margin dynamics and expansion.

STERIS reports 7% revenue growth, anticipates margin improvement ahead

STERIS demonstrated solid revenue growth and maintained free cash flow in line with guidance.
While facing margin challenges in certain segments, the company anticipates improvements ahead.
The outlook for organic revenue growth, adjusted EPS, and free cash flow remains positive for the full year.
Overall, STERIS is strategically positioned to capitalize on growth opportunities and address current challenges.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

STERIS Plc engages in the provision of healthcare and life science products and service solutions. It operates through the following segments: Healthcare, Life Sciences, Applied Sterilization Technologies, and Dental. The Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. The Life Sciences segment designs, manufactures, and sells consumable products, equipment maintenance, specialty services, and capital equipment. The Applied Sterilization Technologies segment is involved in contract sterilization and testing services for medical device and pharmaceutical manufacturers. The Dental segment offers a comprehensive offering for dental practitioners and dental schools, offering instruments, infection prevention consumables and instrument management systems. The company was founded in 1985 and is headquartered in Dublin, Ireland.

Under Armour

Martin Marietta Materials

Thursday's big stock charts feature 3 names with big earnings reports ahead in a market whose attention likely has returned to fundamentals.

3 Big Stock Charts for Thursday: Under Armour, Martin Marietta, and STERIS

Live Nation

Zebra Technologies

Zebra Technologies and TripAdvisor are worth a closer look, but not just because the S&P 500 index updated its list.

The S&P 500 Just Swapped Out 3 Companies. Should Investors Buy on the News?

Investor confidence is high on STERIS (STE) stock for now, thanks to its solid prospects.

Here's Why You Should Add STERIS (STE) to Portfolio Now

The S&P 500 index SPX, +0.01% will have some new members in 2020, after S&P Dow Jones Indices announced a shuffle set to take place just before Christmas.

Live Nation, Zebra and Steris to join S&P 500, TripAdvisor among companies dropped

Steris (STE) reported earnings 30 days ago. What's next for the stock?

Steris (STE) Up 4.5% Since Last Earnings Report: Can It Continue?

STERIS (STE) witnesses solid revenue growth across each of its operating segments in the second quarter of fiscal 2020.

STERIS' (STE) Q2 Earnings Surpass Estimates, FY20 View Up

STERIS' (STE) CEO Walt Rosebrough on Q2 2020 Results - Earnings Call Transcript

Steris (STE) delivered earnings and revenue surprises of 4.76% and 2.93%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Steris (STE) Surpasses Q2 Earnings and Revenue Estimates

Steris (STE) Down 0.1% Since Last Earnings Report: Can It Rebound?

Dublin, Ireland, Aug.  26, 2019  (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) ("STERIS" or the "Company") announced that it will participate in the Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2019. Walt Rosebrough, STERIS’s President and CEO will present at 2:55 p.m. Eastern Time.

STERIS to Participate in the Morgan Stanley Global Healthcare Conference

President & CEO of Steris Plc (30-Year Financial, Insider Trades) Walter M Rosebrough Jr (insider trades) sold 102,500 shares of STE on 08/08/2019 at an average price of $151.78 a share.

Steris Plc (STE) President & CEO Walter M Rosebrough Jr Sold $15.6 million of Shares

STERIS Plc (STE) CEO Walt Rosebrough on Q1 2020 Results - Earnings Call Transcript

STERIS (STE) witnesses solid revenue growth across each of its operating segments in Q1.

STERIS (STE) Q1 Earnings Surpass Estimates, Margins Rise

Steris (STE) delivered earnings and revenue surprises of 10.81% and 3.46%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Steris (STE) Surpasses Q1 Earnings and Revenue Estimates

Teleflex

STERIS (STE) scores higher than Teleflex (TFX) when it comes to valuation and one-year price performance.

TFX or STE: Which is a Better Investment Pick Right Now?

Steris (STE) Up 7.5% Since Last Earnings Report: Can It Continue?

President & CEO of Steris Ltd (NYSE:STE) Walter M Rosebrough Jr sold 119,000 shares of STE on 05/31/2019 at an average price of $132.56 a share.

Steris Ltd (STE) President & CEO Walter M Rosebrough Jr Sold $15.8 million of Shares

STERIS Plc (STE) CEO Walt Rosebrough on Q4 2019 Results - Earnings Call Transcript

STERIS (STE) witnesses solid revenue growth across each of its operating segments in the reported quarter.

STERIS (STE) Q4 Earnings Surpass Estimates, Margins Rise

The healthcare company delivered solid growth in Q4 and beat Wall Street estimates on both the top and bottom lines.

What You'll Want to Know About Steris' Solid Q4 Earnings Results

Mounting operating expenses are weighing on the bottom line of STERIS (STE).

News for STERIS Stock (STE)